IEEE Pulse最新文献

In Late January 2023, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) launched a new center designed to accelerate biomedical discovery and therapeutics, in part by pulling together expert, multidisciplinary teams from throughout the National Institutes of Health (NIH) to quickly respond when national or global health crises strike. The inaugural director of this Center for BME Technology Acceleration, or BETA Center, is biomedical engineer Manu Platt, Ph.D., (Figure 1) who is also taking on the role of NIBIB associate director for scientific diversity, equity, and inclusion. Platt previously held appointments as professor, Wallace H. Coulter distinguished faculty fellow, and diversity director of the Center on Emergent Behaviors of Integrated Cellular Systems and Cellular Manufacturing and Technologies at the Georgia Institute of Technology and Emory University.

The market for injectable drugs is booming, fueling both a wave of innovation in device design and a debate about the relative pros and cons of injectables versus oral medication. As regulators continue to approve injectable medications that could replace daily pill regimens, particularly long-acting drugs that could improve patient compliance, it is legitimate to ask whether injectables will one day become the norm.

Plastic has done more to revolutionize the medical industry over the past century than any other material. Syringes, intravenous bags, personal protective equipment (PPE), catheters, and test kits-plastic is ubiquitous throughout medicine. It's easy to see why. Plastic is low-cost, easy to process, and can be sterilized efficiently.

Since the dawn of additive manufacturing technologies in the 1980s and 90s, now commonly named 3D printing, the possibility of processing raw materials into freeform designed objects with unprecedented shape complexity opened new avenues for the development of medical devices. Indeed, the geometries of nature and the human body are extremely multifaceted, with even fractal- like or multiscale levels of detail, counting with functional gradients of properties, including topology and topography optimizations, to cite some interesting features. In consequence, classical subtracting manufacturing technologies, shape forming tools, and mass production chains are suboptimal for personalizing medical devices and adequately emulating life.

Microbubbles and ultrasound are no longer teaming up only as a way to enhance images. New technologies are now using the two to create physical pathways into cells for easier drug delivery, even into the cells of highly drug-resistant cancerous tumors and across the blood-brain barrier. Going further, a Texas research group has developed drug-carrying microbubbles that can complete targeted delivery themselves, and another group in Missouri has shown that two-way traffic in channels across the blood-brain barrier also allow biomarkers to flow out, which provides a new window into the brain as well as brain diseases.

Despite remarkable advances in the field of prosthetic limbs, existing products still aren't meeting the needs of patients. A 2022 survey found that 44% of upper-limb amputees abandoned their prostheses, citing discomfort, heaviness of the device, and problems with functionality [1].

Even for humans, it can be challenging to recognize, interpret, and respond to emotions. Can artificial intelligence (AI) do any better? Technologies often referred to as "emotion AI" detect and analyze facial expressions, voice patterns, muscle activity, and other behavioral and physiological signals associated with emotions.